MedTrace Logo

Fecal Microbiota Transplantation (FMT) in Multiple Sclerosis

NCT03975413 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1

Last updated 2020-10-08

No results posted yet for this study

Summary

Multiple sclerosis (MS) is a chronic immune central nervous system (CNS) disease of unknown cause. Recent studies suggest that gut microbiota could be a trigger for the neuro-inflammation in MS and abnormal gut microbiota composition has been reported in MS patients. These data provided scientific rationale for microbiota-directed intervention, like stool transplant, for the treatment of MS.

Conditions

  • Multiple Sclerosis, Relapsing-Remitting

Interventions

OTHER

Fecal Microbiota Transplantation (FMT)

Longitudinal FMT study: Baseline, 3 week, 13 week, 26 week, 39 week, 52 week

Sponsors & Collaborators

  • Rush University Medical Center

    lead OTHER

Principal Investigators

  • Ali Keshavarzian, MD · Rush University Medical Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-09-25
Primary Completion
2020-04-01
Completion
2020-05-01

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03975413 on ClinicalTrials.gov